AbbVie and Amgen settle Humira clash

29-09-2017

AbbVie and Amgen settle Humira clash

BCFC / iStockphoto.com

AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.


AbbVie, Amgen, patent, patent infringement, Humira, adalimumab, FDA, BPCIA, biosimilar

LSIPR